A precision oncology revolution is underway at Providence

November 7, 2025

As we mark World Science Day, the work of Carlo Bifulco, M.D., medical director of Cancer Genomics and Precision Oncology, Providence Cancer Institute, takes on new meaning. Dr. Bifulco is helping lead a precision oncology revolution grounded in data, artificial intelligence (AI) and equitable access to cutting-edge cancer care.

Under Dr. Bifulco’s leadership, Providence has expanded its genomics efforts so that patients with advanced cancers benefit from comprehensive genomic profiling.

On the diagnostic front, Dr. Bifulco’s team contributed to Prov-GigaPath, an AI-powered digital-pathology mode trained on 1.3 billion image tiles from 171,000 slides, spanning more than 30,000 people and 31 tissue types. With this tool, patterns invisible to the human eye become visible, which speeds up diagnoses and improves accuracy.

A recent addition to Dr. Bifulco’s body of work is TRIALSCOPE, a joint AI framework from Providence and Microsoft Research that uses real-world data to simulate and validate clinical trial outcomes. In early testing, TRIALSCOPE reproduced results of lung and pancreatic cancer trials using de-identified patient records rather than relying on data collected for a clinical trial.

"Leveraging historical patient data streamlines the process of testing new hypotheses and developing new medications," says Dr. Bifulco.

Scientific advancements for the greater good

Dr. Bifulco and his team unite technological advancements with a strong commitment to accessibility for all. With each innovation, they work to weave genomic testing into routine care and strive to lower barriers to clinical trials, ensuring that diverse populations can benefit from the latest breakthroughs.

On World Science Day, Providence Cancer Institute is proud to recognize Dr. Bifulco and the entire genomics team for their visionary and just pursuits. Find out more about their work.

About Providence Cancer Institute of Oregon

Providence Cancer Institute is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Learn more at-providence.org/ORcancer.-